Andrew J. McRiner

718 total citations
17 papers, 528 citations indexed

About

Andrew J. McRiner is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Andrew J. McRiner has authored 17 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Organic Chemistry and 4 papers in Oncology. Recurrent topics in Andrew J. McRiner's work include Chemical Synthesis and Analysis (5 papers), Cholinesterase and Neurodegenerative Diseases (2 papers) and Cancer therapeutics and mechanisms (2 papers). Andrew J. McRiner is often cited by papers focused on Chemical Synthesis and Analysis (5 papers), Cholinesterase and Neurodegenerative Diseases (2 papers) and Cancer therapeutics and mechanisms (2 papers). Andrew J. McRiner collaborates with scholars based in United States, United Kingdom and China. Andrew J. McRiner's co-authors include Kristina Borstnik, Gary H. Posner, Suji Xie, Theresa A. Shapiro, Surojit Sur, Barbara A. Foster, Timothy J. Donohoe, Peter Sheldrake, Ik‐Hyeon Paik and Jonathan E. Grob and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Organic Letters.

In The Last Decade

Andrew J. McRiner

15 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew J. McRiner United States 10 261 236 146 92 79 17 528
B. Kevin Park United Kingdom 12 212 0.8× 212 0.9× 297 2.0× 53 0.6× 142 1.8× 15 587
Julia Morizzi Australia 12 279 1.1× 492 2.1× 116 0.8× 61 0.7× 58 0.7× 17 703
Ik‐Hyeon Paik United States 7 110 0.4× 173 0.7× 200 1.4× 26 0.3× 93 1.2× 7 396
Konrad Misiura Poland 16 390 1.5× 381 1.6× 58 0.4× 75 0.8× 30 0.4× 67 817
Babita Aneja India 13 188 0.7× 336 1.4× 34 0.2× 83 0.9× 48 0.6× 18 482
José Luís Lavandera Spain 14 237 0.9× 186 0.8× 58 0.4× 41 0.4× 58 0.7× 23 524
Camilo Henrique da Silva Lima Brazil 13 173 0.7× 325 1.4× 60 0.4× 51 0.6× 89 1.1× 62 557
Sebastian Kehr Germany 9 353 1.4× 117 0.5× 132 0.9× 69 0.8× 21 0.3× 9 657
Hardwin O’Dowd United States 13 151 0.6× 277 1.2× 167 1.1× 22 0.2× 97 1.2× 19 467
Christine Latour France 17 152 0.6× 331 1.4× 289 2.0× 66 0.7× 88 1.1× 23 747

Countries citing papers authored by Andrew J. McRiner

Since Specialization
Citations

This map shows the geographic impact of Andrew J. McRiner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. McRiner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. McRiner more than expected).

Fields of papers citing papers by Andrew J. McRiner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. McRiner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. McRiner. The network helps show where Andrew J. McRiner may publish in the future.

Co-authorship network of co-authors of Andrew J. McRiner

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. McRiner. A scholar is included among the top collaborators of Andrew J. McRiner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. McRiner. Andrew J. McRiner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Straley, Kimberly, Iléana Antony‐Debré, Maulasri Bhatta, et al.. (2024). Abstract 5795: Potent and selective degradation of KAT2A and KAT2B induces profound cell state changes and inhibits growth of AML, SCLC and NEPC model systems. Cancer Research. 84(6_Supplement). 5795–5795.
3.
Masilamoni, Gunasingh, et al.. (2022). Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates. Neuropharmacology. 212. 109060–109060. 3 indexed citations
4.
Veerman, Johan J. N., Koen F. W. Hekking, Christopher D. Hupp, et al.. (2021). Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors. ACS Medicinal Chemistry Letters. 12(4). 555–562. 11 indexed citations
5.
Arora, Shilpi, Usha Narayanan, Diana Gikunju, et al.. (2019). Abstract C049: Identification of novel K-Ras G12C inhibitors using a DNA encoded library platform. Molecular Cancer Therapeutics. 18(12_Supplement). C049–C049. 3 indexed citations
6.
Andersen, Jannik N., Andrew J. McRiner, Lynette A. Fouser, et al.. (2019). Abstract 981: Degradation of immuno-oncology targets via proprietary PROTAC platform integrating DNA-encoded library technology and rational drug design. Cancer Research. 79(13_Supplement). 981–981. 1 indexed citations
7.
Keenan, Terence P., Roderick H. Scott, Xianbo Zhou, et al.. (2017). Identification of 5-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophene-2-Carboxamides as Novel and Selective Monoamine Oxidase B Inhibitors Used to Improve Memory and Cognition. ACS Chemical Neuroscience. 8(12). 2746–2758. 5 indexed citations
8.
Jin, Hong, Ting Chen, Dooyoung Lee, et al.. (2016). Intracellular Retention of Three Quinuclidine Derivatives in Caco-2 Permeation Experiments: Mechanisms and Impact on Estimating Permeability and Active Efflux Ratio. Drug Metabolism Letters. 10(3). 161–171. 2 indexed citations
9.
Veerman, Johan J. N., Matthew G. Bursavich, Rebecca Glen, et al.. (2016). Strategic and Tactical Approaches to the Synthesis of 5,6-Dihydro-[1,2,4]oxadiazines. Heterocycles. 92(12). 2166–2166. 10 indexed citations
10.
Meng, Zhaoyang, Andrew J. McRiner, Lianyun Zhao, et al.. (2013). Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(10). 2863–2867. 10 indexed citations
11.
Whitehead, Lewis, Markus Dobler, Branko Radetich, et al.. (2011). Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorganic & Medicinal Chemistry. 19(15). 4626–4634. 129 indexed citations
12.
McRiner, Andrew J., Kristina Borstnik, Wonsuk Chang, et al.. (2006). Biological Mechanisms of Action of Novel C-10 Non-Acetal Trioxane Dimers in Prostate Cancer Cell Lines. Journal of Medicinal Chemistry. 49(26). 7836–7842. 58 indexed citations
13.
Posner, Gary H., Andrew J. McRiner, Ik‐Hyeon Paik, et al.. (2004). Anticancer and Antimalarial Efficacy and Safety of Artemisinin-Derived Trioxane Dimers in Rodents. Journal of Medicinal Chemistry. 47(5). 1299–1301. 106 indexed citations
14.
Posner, Gary H., Surojit Sur, Andrew J. McRiner, et al.. (2003). Orally Active, Antimalarial, Anticancer, Artemisinin-Derived Trioxane Dimers with High Stability and Efficacy. Journal of Medicinal Chemistry. 46(6). 1060–1065. 124 indexed citations
15.
Hodge, Philip, et al.. (2002). A new method for the polymer-supported synthesis of cyclic oligoesters for potential applications in macrocyclic lactone synthesis and combinatorial chemistry. Journal of the Chemical Society Perkin Transactions 1. 629–637. 19 indexed citations
16.
Donohoe, Timothy J., Andrew J. McRiner, Madeleine Helliwell, & Peter Sheldrake. (2001). Use of dissolving metals in the partial reduction of pyridines: formation of 2-alkyl-1,2-dihydropyridines. Journal of the Chemical Society Perkin Transactions 1. 1435–1445. 20 indexed citations
17.
Donohoe, Timothy J., Andrew J. McRiner, & Peter Sheldrake. (2000). Partial Reduction of Electron-Deficient Pyridines. Organic Letters. 2(24). 3861–3863. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026